# US 2021/0275518 A1 · Methods of using rebastinib in the treatment of disorders > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2021/0275518 A1 - Document ID: US20210275518A1 - Status: Published application - Kind: A1 - Application number: 17/193,707 - Filed: 2021-03-05 - Published: 2021-09-09 - Earliest claimed: 2020-03-06 - Assignees: Deciphera Pharmaceuticals, LLC - Applicants: Deciphera Pharmaceuticals, LLC - Inventors: Rodrigo Ruiz Soto; Keisuke Kuida; Haroun Achour - Web page: https://patentgrep.com/patent/US20210275518A1 ## CPC - A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings - A61K 31/282: Platinum compounds - A61K 31/337: having four-membered rings, e.g. taxol - A61K 31/404: Indoles, e.g. pindolol - A61K 31/427: not condensed and containing further heterocyclic rings - A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin - A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline - A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof - A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone - A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine - A61K 31/475: having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine (vincamine A61K31/4375) - A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53}) - A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin - A61K 31/502: ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine - A61K 31/506: not condensed and containing further heterocyclic rings - A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine - A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine - A61K 31/519: ortho- or peri-condensed with heterocyclic rings - A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole - A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate - A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)} - A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid - A61K 33/243: Platinum; Compounds thereof - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61P 35/00: Antineoplastic agents - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Described herein are methods of treating various disorders in patients in need thereof, comprising administering to the patient the compound of Formula (I) or a pharmaceutically acceptable salt thereof. Exemplary disorders that can be treated by the methods described herein include gynecologic carcinosarcomas, endometrial adenocarcinomas, mesotheliomas, ovarian cancers, pancreatic ductal adenocarcinomas, and lung cancers. ## Claims ### Claim 1 A method of treating a gynecologic carcinosarcoma in a patient that has previously received at least one line of treatment for the gynecologic carcinosarcoma, and is in need thereof, comprising administering to the patient an effective amount of the compound of Formula (I): or a pharmaceutically acceptable salt thereof. ### Claim 2 A method of treating a gynecologic carcinosarcoma in a patient that has previously received at least one line of treatment for the gynecologic carcinosarcoma, and is in need thereof, comprising administering to the patient an effective amount of: a) the compound of Formula (I) or a pharmaceutically acceptable salt thereof; and b) paclitaxel. ### Claim 3 (depends on 2) The method of claim 2, wherein after 4 to 6 cycles of treatment with the Compound of Formula (I) and the paclitaxel, or after occurrence of toxicity, the method further comprises administering to the patient an effective amount of the compound of Formula (I) or pharmaceutically acceptable salt thereof until disease progression or toxicity in the patient occurs. ### Claim 4 (depends on 1, 2, 3) The method of any one of claims 1-3, wherein the gynecologic carcinosarcoma is advanced gynecologic carcinosarcoma. ### Claim 5 (depends on 1, 2, 3, 4) The method of any one of claims 1-4, further comprising histologically determining if the gynecologic carcinosarcoma is advanced, persistent or recurrent. ### Claim 6 (depends on 1, 2, 3, 4, 5) The method of any one of claims 1-5, wherein the at least one line of treatment is selected from the group consisting of a chemotherapy treatment, a checkpoint inhibitor treatment, a tyrosine-kinase inhibitor treatment, and a PARP-inhibitor treatment. ### Claim 7 (depends on 6) The method of claim 6, wherein the chemotherapy treatment comprises a chemotherapeutic agent selected from the group consisting of paclitaxel, paclitaxel protein-bound particles for injectable suspension, eribulin, docetaxel, ixabepilone, vincristine, vinorelbine, cisplatin, carboplatin, oxaliplatin, cyclophosphamide, ifosfamide, temozolomide, doxorubicin, pegylated liposomal doxorubicin, daunorubicin, idarubicin, and epirubicin, 5-fluorouracil, capecitabine, cytarabine, decitabine, 5-aza cytadine, gemcitabine, and methotrexate. ### Claim 8 (depends on 6) The method of claim 6, wherein the checkpoint inhibitor treatment comprises an anti-PD1 therapeutic or an anti-PD-L1 therapeutic. ### Claim 9 (depends on 6) The method of claim 6, wherein the tyrosine-kinase inhibitor treatment comprises a tyrosine kinase inhibitor selected from the group consisting of afatinib, axitinib, binimetinib, bosutinib, cabozantinib, cediranib, ceritinib, cobimetinib, crizotinib, dabrafenib, dasatinib, DCC-3014, erlotinib, everolimus, gefitinib, ibrutinib, imatinib, lapatinib, lenvatinib, lestaurtinib, nilotinib, nintedanib, palbociclib, pazopanib, ponatinib, regorafenib, ruxolitinib, semananib, sirolimus, sorafenib, sunitinib, temsirolimus, tofacitinib, trametinib, vandetanib, and vemurafenib. ### Claim 10 (depends on 6) The method of claim 6, wherein the PARP-inhibitor treatment comprises a PARP inhibitor selected from the group consisting of neraparib, olaparib, and rucaparib. ### Claim 11 (depends on 6, 7) The method of claim 6 or claim 7, wherein the chemotherapy treatment comprises paclitaxel and/or carboplatin. ### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11) The method of any one of claims 1-11, wherein the gynecologic carcinosarcoma is of a homologous type or heterologous type. ### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12) The method of any one of claims 1-12, wherein after 28 days or more of administering the compound of Formula (I) or pharmaceutically acceptable salt to the patient, the patient has achieved a partial response condition or a stable disease condition. ### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13) The method of any one of claims 1-13, wherein the gynecologic carcinosarcoma is an endometrial carcinosarcoma. ### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14) The method of any one of claims 1-14, wherein the gynecologic carcinosarcoma is an ovarian carcinosarcoma. ### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15) The method of any one of claims 1-15, wherein the gynecologic carcinosarcoma is a vaginal carcinosarcoma. ### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16) The method of any one of claims 1-16, wherein the gynecologic carcinosarcoma is a cervical carcinosarcoma. ### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17) The method of any one of claims 1-17, comprising administering to the patient about 100 mg of the compound of Formula (I) or pharmaceutically acceptable salt thereof per day. ### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17) The method of any one of claims 1-17, comprising administering to the patient about 150 mg of the compound of Formula (I) or pharmaceutically acceptable salt thereof per day. ### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17) The method of any one of claims 1-17, comprising administering to the patient about 200 mg of the compound of Formula (I) or pharmaceutically acceptable salt thereof per day. ### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20) The method of any one of claims 1-20, wherein the compound of Formula (I) or pharmaceutically acceptable salt thereof is orally administered to the patient. ### Claim 22 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21) The method of any one of claims 2-21, wherein the paclitaxel is intravenously administered to the patient. ### Claim 23 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22) The method of any one of claims 2-22, wherein the paclitaxel is administered to the patient once per week. ### Claim 24 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23) The method of any one of claims 2-23, wherein the paclitaxel is administered to the patient once every three weeks. ### Claim 25 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24) The method of any one of claims 2-24, wherein the paclitaxel is administered to the patient by infusion once per week. ### Claim 26 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25) The method of any one of claims 2-25, wherein the paclitaxel is administered to the patient by infusion once every three weeks. ### Claim 27 A method of treating endometrial adenocarcinoma in a patient in need thereof, comprising administering to the patient an effective amount of the compound of Formula (I) or a pharmaceutically acceptable salt thereof. ### Claim 28 A method for achieving at least a partial response in a patient having endometrial adenocarcinoma, comprising administering to the patient an effective amount of the compound of Formula (I) or a pharmaceutically acceptable salt thereof. ### Claim 29 A method for achieving a stable disease condition in a patient having endometrial adenocarcinoma, comprising administering to the patient an effective amount of the compound of Formula (I) or a pharmaceutically acceptable salt thereof. ### Claim 30 (depends on 27, 28, 29) The method of any one of claims 27-29, wherein the patient has previously been administered at least one prior line of platinum-based therapy. ### Claim 31 (depends on 27, 28, 29, 30) The method of any one of claims 27-30, wherein after 28 days or more of administering the compound of Formula (I) or pharmaceutically acceptable salt thereof to the patient, the patient has at least a partial response or a stable disease condition. ### Claim 32 (depends on 27, 28, 29, 30, 31) The method of any one of claims 27-31, comprising administering to the patient about 100 mg of Formula (I) or pharmaceutically acceptable salt thereof per day. ### Claim 33 (depends on 27, 28, 29, 30, 31) The method of any one of claims 27-31, comprising administering to the patient about 200 mg of the compound of Formula (I) or pharmaceutically acceptable salt thereof per day. ### Claim 34 (depends on 27, 28, 29, 30, 31) The method of any one of claims 27-31, comprising administering to the patient about 150 mg of the compound of Formula (I) or pharmaceutically acceptable salt thereof per day. ### Claim 35 (depends on 27, 28, 29, 30, 31) The method of any one of claims 27-31, comprising administering to the patient about 50 mg of the compound of Formula (I) or pharmaceutically acceptable salt thereof twice per day. ### Claim 36 (depends on 27, 28, 29, 30, 31) The method of any one of claims 27-31, comprising administering to the patient about 100 mg of the compound of Formula (I) or pharmaceutically acceptable salt thereof twice per day. ### Claim 37 (depends on 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) The method of any one of claims 27-36, further comprising administering paclitaxel to the patient. ### Claim 38 (depends on 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37) The method of any one of claims 27-37, wherein the compound of Formula (I) or pharmaceutically acceptable salt thereof is orally administered to the patient. ### Claim 39 (depends on 37, 38) The method of claim 37 or claim 38, wherein the paclitaxel is intravenously administered to the patient. ### Claim 40 (depends on 37, 38, 39) The method of any one of claims 37-39, wherein the paclitaxel is administered to the patient once per week. ### Claim 41 (depends on 37, 38, 39) The method of any one of claims 37-39, wherein the paclitaxel is administered to the patient once every three weeks. ### Claim 42 (depends on 37, 38, 39, 40) The method of any one of claims 37-40, wherein the paclitaxel is administered to the patient by infusion once per week. ### Claim 43 (depends on 37, 38, 39, 41) The method of any one of claims 37-39 or claim 41, wherein the paclitaxel is administered to the patient by infusion once every three weeks. ### Claim 44 A method of treating mesothelioma in a patient in need thereof, comprising administering to the patient about 50 mg to about 200 mg of the compound of Formula (I) or a pharmaceutically acceptable salt thereof per day. ### Claim 45 (depends on 44) The method of claim 44, comprising administering to the patient about 100 mg of the compound of Formula (I) or pharmaceutically acceptable salt thereof per day. ### Claim 46 (depends on 44) The method of claim 44, comprising administering to the patient about 150 mg of the compound of Formula (I) or pharmaceutically acceptable salt thereof per day. ### Claim 47 (depends on 44) The method of claim 44, comprising administering to the patient about 200 mg of Formula (I) or pharmaceutically acceptable salt thereof per day. ### Claim 48 (depends on 44, 45) The method of claim 44 or claim 45, comprising administering to the patient about 50 mg of the compound of Formula (I) or pharmaceutically acceptable salt thereof twice per day. ### Claim 49 (depends on 44, 47) The method of claim 44 or claim 47, comprising administering to the patient about 100 mg of the compound of Formula (I) or pharmaceutically acceptable salt thereof twice per day. ### Claim 50 (depends on 44, 45, 46, 47, 48, 49) The method of any one of claims 44-49, further comprising administering a combination agent to the patient. ### Claim 51 (depends on 50) The method of claim 50, wherein the combination agent is carboplatin. ### Claim 52 (depends on 50) The method of claim 50, wherein the combination agent is paclitaxel. ### Claim 53 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52) The method of any one of claims 44-52, further comprising administering pemetrexed to the patient. ### Claim 54 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53) The method of any one of claims 44-53, wherein the patient has previously been administered at least one prior line of therapy. ### Claim 55 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54) The method of any one of claims 44-54, wherein the at least one prior line of therapy is a platinum-based therapy. ### Claim 56 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55) The method of any one of claims 44-55, wherein the patient has previously been administered carboplatin and/or pemetrexed. ### Claim 57 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56) The method of any one of claims 44-56, wherein the patient has previously been administered cisplatin and/or pemetrexed. ### Claim 58 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57) The method of any one of claims 44-57, wherein the compound of Formula (I) or pharmaceutically acceptable salt thereof is orally administered to the patient. ### Claim 59 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58) The method of any one of claims 44-58, wherein the combination agent is intravenously administered to the patient. ### Claim 60 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59) The method of any one of claims 44-59, wherein the combination agent is intravenously administered to the patient in an amount sufficient to provide an area under the curve of about 5 to about 7. ### Claim 61 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60) The method of any one of claims 44-60, comprising reducing each of the amount of the compound of Formula (I) or pharmaceutically acceptable salt thereof and the combination agent administered to the patient after one or more months of administering to the patient. ### Claim 62 A method for achieving at least a partial response in a patient having mesothelioma, comprising administering to the patient an effective amount of the compound of Formula (I) or a pharmaceutically acceptable salt thereof. ### Claim 63 A method for achieving a stable disease condition in a patient having mesothelioma, comprising administering to the patient the compound of Formula (I) or a pharmaceutically acceptable salt thereof. ### Claim 64 (depends on 62, 63) The method of claim 62 or 63, further comprising administering a combination agent to the patient. ### Claim 65 (depends on 64) The method of claim 64, wherein the combination agent is carboplatin. ### Claim 66 (depends on 64) The method of claim 64, wherein the combination agent is paclitaxel. ### Claim 67 (depends on 62, 63, 64, 65, 66) The method of any one of claims 62-66, further comprising administering pemetrexed to the patient. ### Claim 68 (depends on 62, 63, 64, 65, 66, 67) The method of any one of claims 62-67, wherein the patient has previously been administered at least one prior line of therapy. ### Claim 69 (depends on 68) The method of claim 68, wherein the therapy is a platinum-based therapy. ### Claim 70 (depends on 62, 63, 64, 65, 66, 67, 68, 69) The method of any one of claims 62-69, wherein the patient previously been administered carboplatin and/or pemetrexed. ### Claim 71 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70) The method any one of claims 62-70, wherein the patient previously been administered cisplatin and/or pemetrexed. ### Claim 72 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71) The method of any one of claims 62-71, comprising administering to the patient about 50 mg to about 200 mg of the compound of Formula (I) or pharmaceutically acceptable salt thereof per day. ### Claim 73 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71) The method of any one of claims 62-71, comprising administering to the patient about 50 mg of the compound of Formula (I) or pharmaceutically acceptable salt thereof twice per day. ### Claim 74 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71) The method of any one of claims 62-71, comprising administering to the patient about 100 mg of the compound of Formula (I) or pharmaceutically acceptable salt thereof twice per day. ### Claim 75 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71) The method of any one of claims 62-71, wherein the compound of Formula (I) or pharmaceutically acceptable salt thereof is orally administered to the patient. ### Claim 76 (depends on 64, 65, 66, 67, 68, 69, 70, 71) The method of any one of claims 64-71, wherein the combination agent is intravenously administered to the patient. ### Claim 77 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76) The method of any one of claims 62-76, wherein the combination agent is intravenously administered to the patient in an amount sufficient to provide an area under the curve of about 5 to about 7. ### Claim 78 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77) The method of any one of claims 62-77, comprising reducing each of the amount of the compound of Formula (I) or pharmaceutically acceptable salt thereof and the combination agent administered to the patient after one or more months of administering to the patient. ### Claim 79 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78) The method of any one of claims 62-78, comprising reducing each of the amount of the compound of Formula (I) or pharmaceutically acceptable salt thereof and the combination agent administered to the patient after one or more months of administering to the patient. ### Claim 80 A method of treating ovarian cancer in a patient in need thereof, comprising administering to the patient 50 mg, twice per day, of a compound of Formula (I): and 80 mg/m2 of paclitaxel once per week. ### Claim 81 (depends on 80) The method of claim 80, wherein the patient had received at least one prior platinum therapy. ### Claim 82 (depends on 80, 81) The method of claim 80 or 81, wherein the ovarian cancer is a platinum-resistant ovarian cancer. ### Claim 83 A method of treating ovarian cancer in a patient in need thereof, comprising administering to the patient 100 mg, twice per day, of a compound of Formula (I): and 80 mg/m2 of paclitaxel once per week. ### Claim 84 (depends on 83) The method of claim 83, wherein the patient had received at least one prior platinum therapy. ### Claim 85 (depends on 83, 84) The method of claim 83 or 84, wherein the ovarian cancer is a platinum-resistant ovarian cancer. ### Claim 86 A method of treating pancreatic ductal adenocarcinoma in a patient in need thereof, comprising administering to the patient an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof. ### Claim 87 A method for achieving at least a partial response in a patient having pancreatic ductal adenocarcinoma, comprising administering to the patient an effective amount of the compound of Formula (I) or a pharmaceutically acceptable salt thereof. ### Claim 88 A method for achieving a stable disease condition in a patient having pancreatic ductal adenocarcinoma, comprising administering to the patient an effective amount of the compound of Formula (I) or a pharmaceutically acceptable salt thereof. ### Claim 89 (depends on 86, 87, 88) The method of any one of claims 86-88, wherein the patient has previously been administered at least one prior line of platinum-based therapy. ### Claim 90 (depends on 86, 87, 88, 89) The method of any one of claims 86-89, wherein after 28 days or more of administering the compound of Formula (I) or pharmaceutically acceptable salt thereof to the patient, the patient has at least a partial response or a stable disease condition. ### Claim 91 (depends on 86, 87, 88, 89, 90) The method of any one of claims 86-90, comprising administering to the patient about 100 mg of Formula (I) or pharmaceutically acceptable salt thereof per day. ### Claim 92 (depends on 86, 87, 88, 89, 90) The method of any one of claims 86-90, comprising administering to the patient about 150 mg of the compound of Formula (I) or pharmaceutically acceptable salt thereof per day. ### Claim 93 (depends on 86, 87, 88, 89, 90) The method of any one of claims 86-90, comprising administering to the patient about 200 mg of the compound of Formula (I) or pharmaceutically acceptable salt thereof per day. ### Claim 94 (depends on 86, 87, 88, 89, 90) The method of any one of claims 86-90, comprising administering to the patient about 50 mg of the compound of Formula (I) or pharmaceutically acceptable salt thereof twice per day. ### Claim 95 (depends on 86, 87, 88, 89, 90) The method of any one of claims 86-90, comprising administering to the patient about 100 mg of the compound of Formula (I) or pharmaceutically acceptable salt thereof twice per day. ### Claim 96 (depends on 86, 87, 88, 89, 90, 91, 92, 93, 94, 95) The method of any one of claims 86-95, further comprising administering a combination agent to the patient. ### Claim 97 (depends on 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96) The method of any one of claims 86-96, wherein the compound of Formula (I) or pharmaceutically acceptable salt thereof is orally administered to the patient. ### Claim 98 (depends on 96) The method of claim 96, wherein the combination agent is carboplatin. ### Claim 99 (depends on 96) The method of claim 96, wherein the combination agent is paclitaxel. ### Claim 100 (depends on 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99) The method of any one of claims 86-99, further comprising administering pemetrexed to the patient. ### Claim 101 (depends on 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100) The method of any one of claims 86-100, wherein the patient has previously been administered at least one prior line of therapy. ### Claim 102 (depends on 101) The method of any one of claim 101, wherein the at least one prior line of therapy is a platinum-based therapy. ### Claim 103 (depends on 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102) The method of any one of claims 86-102, wherein the patient has previously been administered carboplatin and/or pemetrexed. ### Claim 104 (depends on 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102) The method of any one of claims 86-102, wherein the patient has previously been administered cisplatin and/or pemetrexed. ### Claim 105 (depends on 96, 97, 98, 99, 100, 101, 102, 103, 104) The method of any one of claims 96-104, wherein the combination agent is intravenously administered to the patient. ### Claim 106 A method of treating lung cancer in a patient in need thereof, comprising administering to the patient an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof. ### Claim 107 A method for achieving at least a partial response in a patient having lung cancer, comprising administering to the patient an effective amount of the compound of Formula (I) or a pharmaceutically acceptable salt thereof. ### Claim 108 A method for achieving a stable disease condition in a patient having lung cancer, comprising administering to the patient an effective amount of the compound of Formula (I) or a pharmaceutically acceptable salt thereof. ### Claim 109 (depends on 106, 107, 108) The method of any one of claims 106-108, wherein the patient has previously been administered at least one prior line of platinum-based therapy. ### Claim 110 (depends on 106, 107, 108, 109) The method of any one of claims 106-109, wherein after 28 days or more of administering the compound of Formula (I) or pharmaceutically acceptable salt thereof to the patient, the patient has at least a partial response or a stable disease condition. ### Claim 111 (depends on 106, 107, 108, 109, 110) The method of any one of claims 106-110, comprising administering to the patient about 100 mg of Formula (I) or pharmaceutically acceptable salt thereof per day. ### Claim 112 (depends on 106, 107, 108, 109, 110) The method of any one of claims 106-110, comprising administering to the patient about 150 mg of the compound of Formula (I) or pharmaceutically acceptable salt thereof per day. ### Claim 113 (depends on 106, 107, 108, 109, 110) The method of any one of claims 106-110, comprising administering to the patient about 200 mg of the compound of Formula (I) or pharmaceutically acceptable salt thereof per day. ### Claim 114 (depends on 106, 107, 108, 109, 110) The method of any one of claims 106-110, comprising administering to the patient about 50 mg of the compound of Formula (I) or pharmaceutically acceptable salt thereof twice per day. ### Claim 115 (depends on 106, 107, 108, 109, 110) The method of any one of claims 106-110, comprising administering to the patient about 100 mg of the compound of Formula (I) or pharmaceutically acceptable salt thereof twice per day. ### Claim 116 (depends on 106, 107, 108, 109, 110, 111, 112, 113, 114, 115) The method of any one of claims 106-115, further comprising administering a combination agent to the patient. ### Claim 117 (depends on 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116) The method of any one of claims 106-116, wherein the compound of Formula (I) or pharmaceutically acceptable salt thereof is orally administered to the patient. ### Claim 118 (depends on 116) The method of claim 116, wherein the combination agent is carboplatin. ### Claim 119 (depends on 116) The method of claim 116, wherein the combination agent is paclitaxel. ### Claim 120 (depends on 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119) The method of any one of claims 106-119, further comprising administering pemetrexed to the patient. ### Claim 121 (depends on 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120) The method of any one of claims 106-120, wherein the patient has previously been administered at least one prior line of therapy. ### Claim 122 (depends on 121) The method of any one of claim 121, wherein the at least one prior line of therapy is a platinum-based therapy. ### Claim 123 (depends on 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122) The method of any one of claims 106-122, wherein the patient has previously been administered carboplatin and/or pemetrexed. ### Claim 124 (depends on 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122) The method of any one of claims 106-122, wherein the patient has previously been administered cisplatin and/or pemetrexed. ### Claim 125 (depends on 116, 117, 118, 119, 120, 121, 122, 123, 124) The method of any one of claims 116-124, wherein the combination agent is intravenously administered to the patient.